Young breast cancer patients represent a unique subgroup, including more advanced stages and have more aggressive tumor biology including higher tumor grade, hormone receptor negative, human epidermal growth factor receptor-2 (HER2) positive, lymphovascular invasion compared to their older counterparts [6, 7]. This evidence concerns the gene ERBB2 and breast cancer.